Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialisation of lifechanging medicines. As a leader in rare disease for more than 25 years, Alexion has developed and commercialised complement inhibitors to treat patients with complement-mediated disorders. Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders. In addition, the company is developing several therapies and focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, metabolic disorders and cardiology.